The Ohio State University Wexner Medical Centre has launched a new clinical trial that uses inhaled nitric oxide to treat coronavirus patients.
Researchers are administrating continuously pulsed inhaled nitric oxide via a Bellerophon INOpulse® delivery system to prevent the progression of the virus in patients with mild to moderate coronavirus-related pneumonia.
The targeted treatment is given to patients who require oxygen but before a ventilator is needed to support breathing.
“There’s a greater likelihood of death among COVID-19 patients with pneumonia who are placed on a ventilator,” said Dr. Sitaramesh Emani, Principal Investigator, Cardiologist at The Ohio State University Wexner Medical Centre.
... to continue reading you must be subscribed
